Healthcare -
Biotechnology - NASDAQ - US
$ 3.74
-1.76 %
$ 385 M
Market Cap
-0.3
P/E
1. INTRINSIC VALUE
Balance Sheet
Alumis Inc. Common Stock
| Current Assets | 306 M |
| Cash & Short-Term Investments | 288 M |
| Receivables | 1.81 M |
| Other Current Assets | 16.1 M |
| Non-Current Assets | 34.8 M |
| Long-Term Investments | 0 |
| PP&E | 33.7 M |
| Other Non-Current Assets | 1.11 M |
| Current Liabilities | 50.9 M |
| Accounts Payable | 9.62 M |
| Short-Term Debt | 1.56 M |
| Other Current Liabilities | 39.7 M |
| Non-Current Liabilities | 30 M |
| Long-Term Debt | 29.2 M |
| Other Non-Current Liabilities | 814 K |
EFFICIENCY
Earnings Waterfall
Alumis Inc. Common Stock
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 301 M |
| Operating Income | -301 M |
| Other Expenses | -6.52 M |
| Net Income | -294 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Alumis Inc. Common Stock
| Net Income | -294 M |
| Depreciation & Amortization | 3.15 M |
| Capital Expenditures | -1.73 M |
| Stock-Based Compensation | 19.5 M |
| Change in Working Capital | 14.8 M |
| Others | 8.04 M |
| Free Cash Flow | -257 M |
Wall Street Analysts Price Targets
Alumis Inc. Common Stock
Wall Street analysts predict an average 1-year price target for ALMS of $22.7 , with forecasts ranging from
a
low of
$13 to a high of $30 .
ALMS Lowest Price Target
Wall Street Target
13 USD
247.59%
ALMS Average Price Target
Wall Street Target
22.7 USD
506.06%
ALMS Highest Price Target
Wall Street Target
30 USD
702.14%
4. DIVIDEND
ANALYSIS
ALMS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Alumis Inc. Common Stock
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
2.31 M USD 6
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alumis to Present at the Jefferies Global Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m.
globenewswire.com
- 3 weeks ago
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
globenewswire.com
- 3 weeks ago
Alumis Completes Merger with ACELYRIN
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned.
globenewswire.com
- 4 weeks ago
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones.
globenewswire.com
- 1 month ago
Alumis Stockholders Approve Merger with ACELYRIN
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC.
globenewswire.com
- 1 month ago
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC.
globenewswire.com
- 1 month ago
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i.
businesswire.com
- 2 months ago
3 Biopharmaceutical Stocks Bucking the Sell-Off
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market.
marketbeat.com
- 2 months ago
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC.
globenewswire.com
- 2 months ago
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis' ESK-001 and leverages Kaken's regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointestinal diseases SOUTH SAN FRANCISCO, Calif. and BUNKYO-KU, Tokyo, March 25, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and Kaken Pharmaceutical Co., Ltd.
globenewswire.com
- 2 months ago
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACELYRIN to create combined company with differentiated late-stage portfolio of therapies and strong balance sheet; expected to close 2Q 2025 – SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the year ended December 31, 2024, and highlighted recent achievements and upcoming milestones.
globenewswire.com
- 3 months ago
Alumis to Present at Leerink's 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40 am ET.
globenewswire.com
- 3 months ago
8. Profile
Summary
Alumis Inc. Common Stock ALMS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 385 M
Dividend Yield
0.00%
Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Contact
280 East Grand Avenue, South San Francisco, CA, 94080
https://www.alumis.com
IPO
Date
Feb. 22, 2021
Employees
168
Officers
Mr. Philip Nunn Ph.D.
Senior Vice President of Pharmacology & Project Team Leader
Mr. Mark Bradley
Chief Development Officer
Mr. Roy C. Hardiman J.D.
Chief Business & Strategy Officer
Dr. David M. Goldstein Ph.D.
Chief Scientific Officer
Ms. Sara Klein
Chief Legal Officer & Corporate Secretary
Mr. Derrick Richardson
Senior Vice President of People & Culture
Ms. Claire Langrish Ph.D.
Senior Vice President & Head of Immunology and Translational Science
Dr. Jorn Drappa M.D., Ph.D.
Chief Medical Officer
Mr. Martin Babler Ph.D.
President, Chief Executive Officer & Chairman
Mr. John R. Schroer C.F.A.
Chief Financial Officer